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Editorial 
Protocol biopsies should not (yet) be the 
standard of care in pediatric renal transplant 
recipients 
The care and management of renal transplant 
recipients, and especially of pediatric renal 
transplant recipients, is potentially complex and 
exacting. Balancing the amount of immunosup-
pression to prevent toxicity and to avoid rejec-
tion is not always straightforward. In addition, 
the specific needs of pediatric patients add 
another layer of complexity to their care. A 
reasonable question is whether routine protocol 
kidney biopsies (by definition, in patients with 
stable renal function) will help to optimize the 
management of pediatric kidney recipients, and 
whether the benefits justify making them the 
standard of care for all pediatric kidney recipi-
ents. I would argue that they do not, and that 
protocol biopsies should not yet be performed 
routinely in all patients. 
There is no question that obtaining renal 
allograft biopsies to evaluate renal dysfunction 
is essentially mandatory. Without a biopsy to 
establish the diagnosis, any therapeutic interven-
tion is a poorly educated guess. However, the use 
of invasive biopsies to evaluate all children with 
stable renal function is another matter. It is 
certainly possible, even likely, that such biopsies, 
preferably in combination with mechanistic stud-
ies of immunologic reactivity, represent import-
ant research tools. They can reveal whether 
important subclinical events are occurring that 
can impact on long-term patient and graft 
survival. Such studies should be performed in 
selected centers with the manpower and expertise 
to perform protocol biopsies safely and rou-
tinely. It is even reasonable for a given center to 
consider them as its standard of care. At issue is 
whether the results from studies that have 
performed protocol biopsies justify their 
expansion to every pediatric kidney transplant 
program. 
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There is a fairly substantial literature on 
protocol biopsies in adult renal transplant recip-
ients, and a smaller literature on pediatric recip-
ients. These studies show a variable incidence of 
subclinical acute rejection, ranging from 2.6-
100%, with many reports in the 25-30% range 
(1-18). There is also a literature demonstrating 
an incidence of subclinical chronic allograft 
nephropathy (CAN) (6, 8, 10, 13, 14, 17-25), 
and a suggestion that the presence of CAN with 
vasculopathy is a poor prognostic factor for 
long-term outcome (8). However, the important 
issue in protocol biopsies is whether performing 
them will lead to management changes that will 
improve long-term graft survival and function. 
The only randomized trial that has demonstrated 
a benefit to diagnosing and treating subclinical 
acute rejection is the adult Winnipeg experience 
and, while it is persuasive, it is a relatively small, 
single center experience (3-6). The pediatric 
protocol biopsy experience from Winnipeg, 
which was not randomized, was associated with 
excellent three-yr graft survival and renal func-
tion, but was associated with an incidence of 
CAN of 86%, despite the aggressive treatment of 
subclinical rejection (26). 
While the risks of protocol biopsies are low, 
they are not zero. Substantial morbidity, and 
even mortality, has been associated with kidney 
transplant biopsies; fortunately, these catastro-
phic complications are rare (12, 27). In patients 
with an indication for a biopsy, the low risk is 
justified by the benefit of knowing the cause of 
the renal dysfunction. In a protocol biopsy 
setting, it is a reasonable question to ask whether 
the risk is justified. By making protocol biopsies 
the standard of care in all programs, there is 
an increased risk of a serious biopsy-related 
adverse event, especially in centers without the 
infrastructure and expertise to perform biopsies 
routinely and safely. There is additionally the 
issue of who will pay for the increased number of 
biopsies. 
While protocol biopsies may be useful in 
centers where there is sufficient expertise to 
perform them and ideally where concomitant 
immunologic studies can be performed, it is not 
clear that there is enough benefit to expand their 
use to every pediatric transplantation program. It 
would certainly be worth considering a large, 
multicenter randomized trial of protocol biopsies 
in pediatric kidney transplant recipients, along 
the lines of the Winnipeg trial, to see if there 
would be a demonstrated benefit, in terms of 
graft survival and function. This would be a 
worthwhile project for either the International 
Pediatric Transplantation Association (IPT A) or 
North American Pediatric Renal Transplant 
Cooperative Study (NAPRTCS) to consider, 
and would provide a real answer to this question. 
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